0001628280-23-001516.txt : 20230125 0001628280-23-001516.hdr.sgml : 20230125 20230125073848 ACCESSION NUMBER: 0001628280-23-001516 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230125 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230125 DATE AS OF CHANGE: 20230125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 23549790 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 abt-20230125.htm 8-K abt-20230125
0000001800FALSENew York Stock ExchangeChicago Stock Exchange, Inc.00000018002023-01-252023-01-250000001800exch:XCHI2023-01-252023-01-250000001800exch:XNYS2023-01-252023-01-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
_______________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
January 25, 2023
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
_______________________________________________________

Illinois1-218936-0698440
(State or other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification  No.)
_______________________________________________________
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class
Trading
Symbol(s)
Name of Each Exchange
on Which Registered
Common Shares, Without Par ValueABT
New York Stock Exchange
Chicago Stock Exchange, Inc.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 2.02    Results of Operations and Financial Condition
On January 25, 2023, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2022.
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, a voluntary recall, certain regulatory costs, certain litigation, the impairment of certain assets, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01    Financial Statements and Exhibits
Exhibit No.Exhibit
104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABBOTT LABORATORIES
Date: January 25, 2023 By:/s/ Robert E. Funck, Jr.
Robert E. Funck, Jr.
Executive Vice President, Finance and Chief Financial Officer

 EX-99.1 2 abt-202212523xexhibitx99111.htm EX-99.1 Document

Exhibit 99.1
image.jpg
  News Release

Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook

–Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion
–Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent
–Full-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34
–Continues to strengthen portfolio with steady cadence of new product approvals
ABBOTT PARK, Ill., Jan. 25, 2023 — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2022.

•Fourth-quarter sales of $10.1 billion, which were negatively impacted by an expected year-over-year decline in COVID-19 testing-related sales, decreased 12.0 percent on a reported basis and
6.1 percent on an organic basis, which excludes the impact of foreign exchange.
•Excluding COVID-19 testing-related sales1, fourth-quarter sales decreased 1.4 percent on a reported basis and increased 5.4 percent on an organic basis.
•Excluding COVID-19 testing-related sales2 and U.S. infant formula sales that were impacted by manufacturing disruptions3, full-year 2022 sales increased 1.9 percent on a reported basis and 7.4 percent on an organic basis.
•GAAP diluted EPS was $0.59 in the fourth quarter. Excluding specified items, adjusted diluted EPS was $1.03.
•Abbott issues full-year 2023 guidance for diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25 and full-year adjusted EPS from continuing operations of $4.30 to $4.50.
•Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits4 and COVID-19 testing-related sales of around $2.0 billion.
•In October, Abbott's market-leading FreeStyle Libre® continuous glucose monitoring system was named the "Best Medical Technology" of the last 50 years by the Galien Foundation.
•In December, Abbott announced U.S. Food and Drug Administration (FDA) approval of its EternaTM spinal cord stimulation system — the smallest implantable, rechargeable system currently available for the treatment of chronic pain.5
•In January, Abbott announced U.S. FDA approval of its minimally invasive NavitorTM transcatheter aortic valve implantation (TAVI) system for people with severe aortic stenosis who are at high risk for surgery.

"We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions," said Robert B. Ford, chairman and chief executive officer, Abbott. "Our R&D pipeline continues to be highly productive with several recent and upcoming new product launches that position us well going forward."
-- more -- 
Page 1 of 19

FOURTH-QUARTER BUSINESS OVERVIEW
Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange. In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the business in the fourth quarter ended December 31, 2022 as well as in 2023 as the COVID-19 pandemic shifts to an endemic state, resulting in significantly lower expected demand for COVID-19 tests.
Total Company
($ in millions)
% Change vs. 4Q21
Sales 4Q22ReportedOrganic
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total 6
4,219 5,872 10,091 (13.1)(11.2)(12.0)(13.1)(0.9)(6.1)
Nutrition795 1,022 1,817 (14.4)(8.3)(11.1)(14.4)1.4 (5.7)
Diagnostics1,695 1,610 3,305 (29.0)(22.8)(26.1)(29.0)(12.5)(21.3)
Established Pharmaceuticals— 1,216 1,216 n/a1.0 1.0 n/a7.9 7.9 
Medical Devices1,726 2,024 3,750 12.2 (8.4)— 12.2 4.1 7.4 
% Change vs. 12M21
Sales 12M22ReportedOrganic
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total 6
18,142 25,511 43,653 9.0 (3.5)1.3 9.0 4.7 6.4 
Nutrition2,919 4,540 7,459 (17.9)(4.2)(10.1)(17.9)2.5 (6.2)
Diagnostics8,646 7,938 16,584 21.3 (6.8)6.0 21.3 1.3 10.4 
Established Pharmaceuticals— 4,912 4,912 n/a4.1 4.1 n/a10.6 10.6 
Medical Devices6,566 8,121 14,687 10.9 (3.8)2.2 10.9 6.2 8.1 
n/a = Not Applicable.


Worldwide COVID-19 testing-related sales were $1.069 billion in the fourth quarter of 2022 compared to $2.319 billion in the fourth quarter of the prior year. Worldwide COVID-19 testing-related sales were $8.368 billion in the full year of 2022 compared to $7.679 billion in the prior year.

The following tables summarize sales excluding COVID-19 testing-related sales and the change in reported and organic sales excluding COVID-19 testing-related sales in 2022 versus the prior year2:
% Change vs. 4Q21
Sales excl. COVID tests 4Q22Reported excl. COVID testsOrganic excl. COVID tests
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total 1
3,443 5,579 9,022 5.8 (5.4)(1.4)5.8 5.3 5.4 
Diagnostics
919 1,317 2,236 16.8 (3.6)3.8 16.8 8.0 11.2 
% Change vs. 12M21
Sales excl. COVID tests 12M22Reported excl. COVID testsOrganic excl. COVID tests
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total
12,644 22,641 35,285 2.5 (1.8)(0.3)2.5 6.5 5.1 
Diagnostics
3,148 5,068 8,216 11.4 (1.4)3.1 11.4 7.1 8.6 

-- more --
Page 2 of 19

Nutrition
($ in millions)
% Change vs. 4Q21
Sales 4Q22ReportedOrganic
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total795 1,022 1,817 (14.4)(8.3)(11.1)(14.4)1.4 (5.7)
Pediatric454 428 882 (20.4)(8.9)(15.2)(20.4)(1.2)(11.8)
Adult341 594 935 (4.8)(7.9)(6.8)(4.8)3.4 0.5 
% Change vs. 12M21
Sales 12M22ReportedOrganic
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total2,919 4,540 7,459 (17.9)(4.2)(10.1)(17.9)2.5 (6.2)
Pediatric1,562 1,919 3,481 (28.7)(8.9)(19.0)(28.7)(3.9)(16.6)
Adult1,357 2,621 3,978 (0.5)(0.4)(0.4)(0.5)7.6 4.8 

Worldwide Nutrition sales decreased 11.1 percent on a reported basis and 5.7 percent on an organic basis in the fourth quarter. Total worldwide Nutrition and Pediatric Nutrition sales were negatively impacted as a result of manufacturing disruptions during 2022 of certain infant formula products3 at Abbott's Sturgis, Michigan, facility. The manufacturing facility has subsequently restarted production.

In Adult Nutrition, global sales decreased 6.8 percent on a reported basis and increased 0.5 percent on an organic basis in the fourth quarter, led by Ensure®, Abbott's market-leading complete and balanced nutrition brand.


-- more --
Page 3 of 19

Diagnostics
($ in millions)
% Change vs. 4Q21
Sales 4Q22ReportedOrganic
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total1,695 1,610 3,305 (29.0)(22.8)(26.1)(29.0)(12.5)(21.3)
Core Laboratory301 963 1,264 0.2 (8.1)(6.3)0.2 3.5 2.8 
Molecular62 118 180 (54.2)(43.9)(47.9)(54.2)(38.6)(44.7)
Point of Care88 43 131 (7.6)7.0 (3.3)(7.6)14.4 (1.2)
Rapid Diagnostics1,244 486 1,730 (33.0)(38.2)(34.5)(33.0)(28.3)(31.6)
% Change vs. 12M21
Sales 12M22ReportedOrganic
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total8,646 7,938 16,584 21.3 (6.8)6.0 21.3 1.3 10.4 
Core Laboratory1,137 3,751 4,888 (0.7)(5.8)(4.7)(0.7)2.7 1.9 
Molecular370 625 995 (34.6)(27.4)(30.3)(34.6)(22.6)(27.4)
Point of Care372 153 525 (3.2)0.8 (2.1)(3.2)6.0 (0.6)
Rapid Diagnostics6,767 3,409 10,176 34.4 (3.1)19.0 34.4 5.4 22.5 
As expected, Diagnostics sales in the fourth quarter were negatively impacted by year-over-year declines in COVID-19 testing-related sales. Worldwide COVID-19 testing-related sales were $1.069 billion in the fourth quarter of 2022 compared to $2.319 billion in the fourth quarter of the prior year.

The following tables summarize sales excluding COVID-19 testing-related sales and the change in reported and organic sales excluding COVID-19 testing-related sales in 2022 versus the prior year2:
% Change vs. 4Q21
Sales excl. COVID tests 4Q22Reported excl. COVID testsOrganic excl. COVID tests
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total
919 1,317 2,236 16.8 (3.6)3.8 16.8 8.0 11.2 
Core Laboratory298 956 1,254 1.5 (5.3)(3.8)1.5 6.8 5.6 
Molecular45 98 143 (0.2)(8.3)(5.9)(0.2)(0.4)(0.3)
Point of Care88 43 131 (7.6)7.0 (3.3)(7.6)14.4 (1.2)
Rapid Diagnostics488 220 708 38.3 4.6 25.7 38.3 16.8 30.3 

% Change vs. 12M21
Sales excl. COVID tests 12M22Reported excl. COVID testsOrganic excl. COVID tests
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total
3,148 5,068 8,216 11.4 (1.4)3.1 11.4 7.1 8.6 
Core Laboratory1,121 3,705 4,826 1.3 (2.9)(2.0)1.3 5.8 4.8 
Molecular180 404 584 11.4 8.0 9.0 11.4 14.8 13.8 
Point of Care372 153 525 (3.2)0.8 (2.1)(3.2)6.0 (0.6)
Rapid Diagnostics1,475 806 2,281 25.6 1.3 15.8 25.6 9.4 19.1 

-- more --
Page 4 of 19

Established Pharmaceuticals
($ in millions)
% Change vs. 4Q21
Sales 4Q22ReportedOrganic
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total— 1,216 1,216 n/a1.0 1.0 n/a7.9 7.9 
Key Emerging Markets— 902 902 n/a3.9 3.9 n/a10.3 10.3 
Other— 314 314 n/a(6.5)(6.5)n/a1.9 1.9 
% Change vs. 12M21
Sales 12M22ReportedOrganic
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total— 4,912 4,912 n/a4.1 4.1 n/a10.6 10.6 
Key Emerging Markets— 3,728 3,728 n/a5.4 5.4 n/a11.8 11.8 
Other— 1,184 1,184 n/a0.4 0.4 n/a7.3 7.3 

Established Pharmaceuticals sales increased 1.0 percent on a reported basis and 7.9 percent on an organic basis in the fourth quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 3.9 percent on a reported basis and 10.3 percent on an organic basis, led by strong growth in several geographies including India, China, Brazil and Mexico, and across several therapeutic areas, including cardiometabolic, women's health and central nervous system/pain management.




-- more --
Page 5 of 19

Medical Devices
($ in millions)
% Change vs. 4Q21
Sales 4Q22ReportedOrganic
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total1,726 2,024 3,750 12.2 (8.4)— 12.2 4.1 7.4 
Rhythm Management254 260 514 5.2 (13.3)(5.0)5.2 (0.5)2.1 
Electrophysiology242 245 487 22.7 (19.8)(3.1)22.7 (6.6)4.9 
Heart Failure171 59 230 0.1 (13.9)(3.9)0.1 (4.5)(1.2)
Vascular214 391 605 (7.5)(12.5)(10.8)(7.5)(1.4)(3.5)
Structural Heart214 227 441 10.9 0.4 5.2 10.9 15.7 13.5 
Neuromodulation163 39 202 3.7 (3.1)2.3 3.7 11.7 5.3 
Diabetes Care468 803 1,271 34.9 (2.5)8.6 34.9 9.8 17.3 
% Change vs. 12M21
Sales 12M22ReportedOrganic
U.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Total6,566 8,121 14,687 10.9 (3.8)2.2 10.9 6.2 8.1 
Rhythm Management1,029 1,090 2,119 1.1 (7.7)(3.6)1.1 1.9 1.5 
Electrophysiology909 1,018 1,927 17.0 (9.9)1.1 17.0 0.7 7.3 
Heart Failure694 226 920 6.2 (4.0)3.5 6.2 5.2 5.9 
Vascular864 1,619 2,483 (5.6)(6.9)(6.4)(5.6)1.5 (1.0)
Structural Heart818 894 1,712 12.0 1.6 6.3 12.0 13.8 13.0 
Neuromodulation619 151 770 0.3 (8.1)(1.4)0.3 2.9 0.9 
Diabetes Care1,633 3,123 4,756 34.8 0.2 9.9 34.8 10.6 17.4 


Worldwide Medical Devices sales were flat on a reported basis and increased 7.4 percent on an organic basis in the fourth quarter. Sales growth in the U.S. was led by strong double-digit growth in Electrophysiology, Structural Heart and Diabetes Care. Internationally, sales growth was negatively impacted by intermittent COVID-19 lockdown restrictions in China as well as supply constraints in certain areas, including Electrophysiology and Diabetes Care.

In Diabetes Care, FreeStyle Libre sales were approximately $1.1 billion in the quarter, including U.S. growth of more than 40 percent.

In 2022, Abbott continued to strengthen its Medical Devices portfolio with several recent pipeline advancements, including U.S. FDA approvals of:
•Navitor, Abbott's latest generation transcatheter aortic valve implantation (TAVI) system, used for the treatment of severe aortic stenosis.
•Eterna, Abbott's rechargeable spinal cord stimulator used for treating chronic pain.
•AveirTM leadless pacemaker, used for treating patients with slow heart rhythms.
•An expanded indication of use for CardioMEMSTM HF remote monitoring system, which detects early warning signs of worsening heart failure.
•U.S. FDA clearance of the FreeStyle Libre 3 system, which provides continuous glucose readings and unsurpassed 14-day accuracy7 in the world's smallest and thinnest7 wearable sensor.

-- more --
Page 6 of 19

ABBOTT'S EARNINGS-PER-SHARE GUIDANCE
Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of $3.05 to $3.25. Abbott forecasts specified items for the full-year 2023 of $1.25 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for the full-year 2023.
ABBOTT DECLARES 396TH CONSECUTIVE QUARTERLY DIVIDEND
On Dec. 9, 2022, the board of directors of Abbott declared the company's quarterly dividend of $0.51 per share. Abbott's cash dividend is payable Feb. 15, 2023, to shareholders of record at the close of business on Jan. 13, 2023.

Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.


About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.
Abbott will live-webcast its fourth-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
-- more --
Page 7 of 19

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Abbott Financial:
Scott Leinenweber, 224-668-0791
Michael Comilla, 224-668-1872
Ryan Aliff, 224-667-2299
Abbott Media:
Karen Twigg May, 224-668-2681
Kate Dyer, 224-668-9965
1In the fourth quarter of 2022, COVID-19 testing-related sales were $1.069 billion. In the fourth quarter of 2021, total worldwide sales were $11.468 billion, which included U.S. sales of $4.855 billion and International sales of $6.613 billion. In the fourth quarter of 2021, COVID-19 testing-related sales were $2.319 billion.
2For the full-year 2022, COVID-19 testing-related sales were $8.368 billion. In 2021, total worldwide sales were $43.075 billion, which included U.S. sales of $16.642 billion and International sales of $26.433 billion. For the full-year 2021, COVID-19 testing-related sales were $7.679 billion. Diagnostic sales and COVID-19 testing-related sales in 2022 and 2021 are summarized below:
Sales 4Q22COVID Tests Sales 4Q22
U.S.Int'lTotalU.S.Int'lTotal
Total Diagnostics
1,695 1,610 3,305 776 293 1,069 
Core Laboratory301 963 1,264 3 7 10 
Molecular62 118 180 17 20 37 
Rapid Diagnostics1,244 486 1,730 756 266 1,022 
Sales 4Q21COVID Tests Sales 4Q21
U.S.Int'lTotalU.S.Int'lTotal
Total Diagnostics
2,386 2,085 4,471 1,600 719 2,319 
Core Laboratory300 1,048 1,348 7 39 46 
Molecular135 210 345 89 103 192 
Rapid Diagnostics1,856 787 2,643 1,504 577 2,081 
Sales 12M22COVID Tests Sales 12M22
U.S.Int'lTotalU.S.Int'lTotal
Total Diagnostics
8,646 7,938 16,584 5,498 2,870 8,368 
Core Laboratory1,137 3,751 4,888 16 46 62 
Molecular370 625 995 190 221 411 
Rapid Diagnostics6,767 3,409 10,176 5,292 2,603 7,895 
Sales 12M21COVID Tests Sales 12M21
U.S.Int'lTotalU.S.Int'lTotal
Total Diagnostics
7,129 8,515 15,644 4,302 3,377 7,679 
Core Laboratory1,145 3,983 5,128 37 167 204 
Molecular566 861 1,427 405 487 892 
Rapid Diagnostics5,034 3,519 8,553 3,860 2,723 6,583 
3U.S. sales of certain infant formula products impacted by the 2022 manufacturing disruptions were $202 million in 4Q22 and $329 million in 4Q21 and $479 million for the full-year 2022 and $1.229 billion for the full-year 2021. Excluding COVID-19 testing-related sales and U.S. infant formula sales that were impacted by manufacturing disruptions, fourth-quarter sales were flat on a reported basis and increased 7.1 percent on an organic basis.
4Abbott has not provided the GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth.
5Abbott. Eterna SCS IPG Size Comparison Memo (MAT-2210151); 2022.
6Total Abbott sales include Other Sales of approximately $3 million in 4Q22 and approximately $11 million in 12M22.
7Data on file, Abbott Diabetes Care. Comparison based on publicly available information.

-- more --
Page 8 of 19

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Fourth Quarter Ended December 31, 2022 and 2021
(in millions, except per share data)
(unaudited)




4Q224Q21% Change
Net Sales$10,091$11,468(12.0)
Cost of products sold, excluding amortization expense4,593 4,766 (3.6)
Amortization of intangible assets496 514 (3.7)
Research and development725 762 (4.8)
Selling, general, and administrative2,973 3,048 (2.5)
Total Operating Cost and Expenses8,787 9,090 (3.3)
Operating Earnings1,304 2,378 (45.2)
Interest expense, net66 120 (45.2)
Net foreign exchange (gain) loss(14)(6)n/m
Other (income) expense, net(68)(63)8.1 
Earnings before taxes1,320 2,327 (43.3)
Taxes on earnings287 338 (15.2)1)
Net Earnings$1,033$1,989(48.1)
Net Earnings excluding Specified Items, as described below$1,811$2,366(23.4)2)
Diluted Earnings per Common Share$0.59$1.11(46.8)
Diluted Earnings per Common Share,
excluding Specified Items, as described below
$1.03$1.32(22.0)2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
1,754 1,782 


NOTES:
See tables on page 13 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
-- more --
Page 9 of 19

1)2021 Taxes on Earnings includes the recognition of approximately $40 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $45 million in excess tax benefits associated with share-based compensation.

2)2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $778 million, or $0.44 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.
2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $377 million, or $0.21 per share, for intangible amortization and other expenses primarily associated with restructuring actions and acquisitions, partially offset by a change in estimate to the restructuring actions recognized in the second quarter of 2021 related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.


-- more --
Page 10 of 19

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Twelve Months Ended December 31, 2022 and 2021
(in millions, except per share data)
(unaudited)




12M2212M21% Change
Net Sales$43,653$43,0751.3 
Cost of products sold, excluding amortization expense19,142 18,537 3.3 
Amortization of intangible assets2,013 2,047 (1.7)
Research and development2,888 2,742 5.3 
Selling, general, and administrative11,248 11,324 (0.7)
Total Operating Cost and Expenses35,291 34,650 1.8 
Operating Earnings8,362 8,425 (0.7)
Interest expense, net375 490 (23.4)
Net foreign exchange (gain) loss2 1 n/m
Other (income) expense, net(321)(277)16.0 
Earnings before taxes8,306 8,211 1.2 
Taxes on earnings1,373 1,140 20.5 1)
Net Earnings$6,933$7,071(2.0)
Net Earnings excluding Specified Items, as described below$9,466$9,3671.1 2)
Diluted Earnings per Common Share$3.91$3.94(0.8)
Diluted Earnings per Common Share,
excluding Specified Items, as described below
$5.34$5.212.5 2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
1,764 1,789 




NOTES:
See tables on page 14 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.



-- more --
Page 11 of 19

1)2022 Taxes on Earnings includes the recognition of approximately $20 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $43 million in excess tax benefits associated with share-based compensation.

2021 Taxes on Earnings includes the recognition of approximately $55 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $145 million in excess tax benefits associated with share-based compensation.


2)2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.533 billion, or $1.43 per share, for intangible amortization, charges related to a voluntary recall and restructuring actions, the impairment of R&D intangible assets, acquisition-related costs and other net expenses.
2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.296 billion, or $1.27 per share, for intangible amortization and other net expenses primarily associated with restructuring actions, certain litigation and acquisitions.

-- more --
Page 12 of 19

Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Fourth Quarter Ended December 31, 2022 and 2021
(in millions, except per share data)
(unaudited)
4Q22
As
Reported (GAAP)		Specified ItemsAs
Adjusted
Intangible Amortization
$496 $(496)$— 
Gross Margin
5,002 612 5,614 
R&D
725 (71)654 
SG&A
2,973 (144)2,829 
Other (income) expense, net
(68)(24)(92)
Earnings before taxes
1,320 851 2,171 
Taxes on Earnings
287 73 360 
Net Earnings
1,033 778 1,811 
Diluted Earnings per Share
$0.59 $0.44 $1.03 

Specified items reflect intangible amortization expense of $496 million and other net expenses of $355 million associated with restructuring actions, costs associated with acquisitions and other expenses. See page 16 for additional details regarding specified items.
4Q21
As
Reported (GAAP)		Specified ItemsAs
Adjusted
Intangible Amortization
$514 $(514)$— 
Gross Margin
6,188 434 6,622 
R&D
762 (39)723 
SG&A
3,048 (43)3,005 
Other (income) expense, net
(63)(5)(68)
Earnings before taxes
2,327 521 2,848 
Taxes on Earnings
338 144 482 
Net Earnings
1,989 377 2,366 
Diluted Earnings per Share
$1.11 $0.21 $1.32 

Specified items reflect intangible amortization expense of $514 million and other net expenses of $7 million that includes costs associated with acquisitions and other expenses, partially offset by a change in estimate to the restructuring actions recognized in the second quarter of 2021. See page 17 for additional details regarding specified items.
-- more --
Page 13 of 19

Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Twelve Months Ended December 31, 2022 and 2021
(in millions, except per share data)
(unaudited)
12M22
As
Reported (GAAP)		Specified ItemsAs
Adjusted
Intangible Amortization
$2,013 $(2,013)$— 
Gross Margin
22,498 2,351 24,849 
R&D
2,888 (282)2,606 
SG&A
11,248 (236)11,012 
Other (income) expense, net
(321)(55)(376)
Earnings before taxes
8,306 2,924 11,230 
Taxes on Earnings
1,373 391 1,764 
Net Earnings
6,933 2,533 9,466 
Diluted Earnings per Share
$3.91 $1.43 $5.34 
Specified items reflect intangible amortization expense of $2.013 billion and other net expenses of $911 million that includes charges for the impairment of R&D intangible assets, costs associated with a product recall and restructuring actions, acquisition-related costs, and other net expenses. See page 18 for additional details regarding specified items.
12M21
As
Reported (GAAP)		Specified ItemsAs
Adjusted
Intangible Amortization
$2,047 $(2,047)$— 
Gross Margin
22,491 2,476 24,967 
R&D
2,742 (106)2,636 
SG&A
11,324 (317)11,007 
Other (income) expense, net
(277)25 (252)
Earnings before taxes
8,211 2,874 11,085 
Taxes on Earnings
1,140 578 1,718 
Net Earnings
7,071 2,296 9,367 
Diluted Earnings per Share
$3.94 $1.27 $5.21 

Specified items reflect intangible amortization expense of $2.047 billion and other net expenses of $827 million, primarily associated with restructuring actions, certain litigation, acquisitions and other expenses. See page 19 for additional details regarding specified items.


-- more --
Page 14 of 19

A reconciliation of the fourth-quarter tax rates for 2022 and 2021 is shown below:
4Q22
($ in millions)Pre-Tax
Income		Taxes on
Earnings		Tax
Rate
As reported (GAAP)$1,320 $287 21.7 % 
Specified items851 73 
Excluding specified items$2,171 $360 16.5 %
4Q21
($ in millions)Pre-Tax
Income		Taxes on
Earnings		Tax
Rate
As reported (GAAP)$2,327 $338 14.5 %1)
Specified items521 144 
Excluding specified items$2,848 $482 16.9 %

1)2021 Taxes on Earnings includes the recognition of approximately $40 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $45 million in excess tax benefits associated with share-based compensation.
A reconciliation of the year-to-date tax rates for 2022 and 2021 is shown below:
12M22
($ in millions)Pre-Tax
Income		Taxes on
Earnings		Tax
Rate
As reported (GAAP)$8,306 $1,373 16.5 %2)
Specified items2,924 391 
Excluding specified items$11,230 $1,764 15.7 %
12M21
($ in millions)Pre-Tax
Income		Taxes on
Earnings		Tax
Rate
As reported (GAAP)$8,211 $1,140 13.9 %3)
Specified items2,874 578 
Excluding specified items$11,085 $1,718 15.5 %
2)2022 Taxes on Earnings includes the recognition of approximately $20 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $43 million in excess tax benefits associated with share-based compensation.

3)2021 Taxes on Earnings includes the recognition of approximately $55 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $145 million in excess tax benefits associated with share-based compensation.
-- more --
Page 15 of 19

Abbott Laboratories and Subsidiaries
Details of Specified Items
Fourth Quarter Ended December 31, 2022
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		Restructuring
and Cost
Reduction
Initiatives (b)		Intangible
Amortization		Other (c)Total
Specifieds
Gross Margin$23 $87 $496 $6 $612 
R&D(6)(34)— (31)(71)
SG&A(7)(135)— (2)(144)
Other (income) expense, net3 — — (27)(24)
Earnings before taxes$33 $256 $496 $66 851 
Taxes on Earnings (d)73 
Net Earnings$778 
Diluted Earnings per Share$0.44 
The table above provides additional details regarding the specified items described on page 13.
a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.
b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products as well as the impairment of an equity investment.
d)Reflects the net tax benefit associated with the specified items.



-- more --
Page 16 of 19

Abbott Laboratories and Subsidiaries
Details of Specified Items
Fourth Quarter Ended December 31, 2021
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		Restructuring
and Cost
Reduction
Initiatives (b)		Intangible
Amortization		Other (c)Total
Specifieds
Gross Margin$26 $(110)$514 $4 $434 
R&D(6)(8)— (25)(39)
SG&A(12)(23)— (8)(43)
Other (income) expense, net(2)— — (3)(5)
Earnings before taxes$46 $(79)$514 $40 521 
Taxes on Earnings (d)144 
Net Earnings$377 
Diluted Earnings per Share$0.21 

The table above provides additional details regarding the specified items described on page 13.
a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.
b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes a credit associated with a change in estimate to the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.
c)Other includes incremental costs to comply with the European Union's MDR and IVDR requirements for previously approved products.
d)Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

-- more --
Page 17 of 19

Abbott Laboratories and Subsidiaries
Details of Specified Items
Twelve Months Ended December 31, 2022
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-related (a)		Restructuring
and Cost
Reduction
Initiatives (b)		Intangible
Amortization		Other (c)Total
Specifieds
Gross Margin$79 $86 $2,013 $173 $2,351 
R&D(16)(38)— (228)(282)
SG&A(38)(140)— (58)(236)
Other (income) expense, net(12)— — (43)(55)
Earnings before taxes$145 $264 $2,013 $502 2,924 
Taxes on Earnings (d)391 
Net Earnings$2,533 
Diluted Earnings per Share$1.43 
The table above provides additional details regarding the specified items described on page 14.

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.
b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. The Gross Margin amount includes a credit associated with the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests.
c)Other primarily relates to the net costs related to a voluntary recall within the Nutrition segment, charges associated with the impairments of R&D intangible assets and an equity investment acquired in a business combination, incremental costs to comply with the European Union's MDR and IVDR Regulations for previously approved products and costs related to certain litigation.
d)Reflects the net tax benefit associated with the specified items, excess tax benefits associated with share-based compensation and net tax expense as a result of the resolution of various tax positions related to prior years.

-- more --
Page 18 of 19

Abbott Laboratories and Subsidiaries
Details of Specified Items
Twelve Months Ended December 31, 2021
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		Restructuring
and Cost
Reduction
Initiatives (b)		Intangible
Amortization		Other (c)Total
Specifieds
Gross Margin$82 $323 $2,047 $24 $2,476 
R&D(15)(7)— (84)(106)
SG&A(55)(45)— (217)(317)
Other (income) expense, net1 1 — 23 25 
Earnings before taxes$151 $374 $2,047 $302 2,874 
Taxes on Earnings (d)578 
Net Earnings$2,296 
Diluted Earnings per Share$1.27 
The table above provides additional details regarding the specified items described on page 14.
a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.
b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes charges associated with a restructuring plan to align Abbott's manufacturing network for COVID-19 diagnostic tests with changes during the year in current and projected testing demand.
c)Other primarily relates to the costs related to certain litigation, the acquisition of a research and development asset, the impairments of an equity investment and an intangible asset, and the gain on the disposition of an equity method investment.
d)Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

















###
Page 19 of 19
 EX-101.SCH 3 abt-20230125.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 abt-20230125_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 abt-20230125_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Document Information [Line Items] Document Information [Line Items] Title of 12(b) Security Title of 12(b) Security Exchange [Domain] Exchange [Domain] Amendment Flag Amendment Flag NYSE CHICAGO, INC. NYSE CHICAGO, INC. [Member] Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Entity Tax Identification Number Entity Tax Identification Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Local Phone Number Local Phone Number Written Communications Written Communications Cover [Abstract] NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Document Type Document Type Document Information [Table] Document Information [Table] Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 abt-20230125_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 image.jpg begin 644 image.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Jan. 25, 2023
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Jan. 25, 2023
Entity Registrant Name ABBOTT LABORATORIES
Entity Incorporation, State or Country Code IL
Entity File Number 1-2189
Entity Tax Identification Number 36-0698440
Entity Address, Address Line One 100 Abbott Park Road
Entity Address, City or Town Abbott Park
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 224
Local Phone Number 667-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000001800
Amendment Flag false
NYSE CHICAGO, INC.  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name CHX
NEW YORK STOCK EXCHANGE, INC.  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name NYSE
XML 9 abt-20230125_htm.xml IDEA: XBRL DOCUMENT 0000001800 2023-01-25 2023-01-25 0000001800 exch:XCHI 2023-01-25 2023-01-25 0000001800 exch:XNYS 2023-01-25 2023-01-25 0000001800 false NYSE CHX 8-K 2023-01-25 ABBOTT LABORATORIES IL 1-2189 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 false false false false Common Shares, Without Par Value Common Shares, Without Par Value ABT ABT NYSE CHX false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 3 22 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://abbott.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - abt-20230125.htm 4 abt-20230125.htm abt-202212523xexhibitx99111.htm abt-20230125.xsd abt-20230125_def.xml abt-20230125_lab.xml abt-20230125_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abt-20230125.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 27 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "abt-20230125_def.xml" ] }, "inline": { "local": [ "abt-20230125.htm" ] }, "labelLink": { "local": [ "abt-20230125_lab.xml" ] }, "presentationLink": { "local": [ "abt-20230125_pre.xml" ] }, "schema": { "local": [ "abt-20230125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 2, "nsprefix": "abt", "nsuri": "http://abbott.com/20230125", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abt-20230125.htm", "contextRef": "if151fdc50140459d99d66e16b82274b1_D20230125-20230125", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://abbott.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abt-20230125.htm", "contextRef": "if151fdc50140459d99d66e16b82274b1_D20230125-20230125", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NYSE CHICAGO, INC. [Member]", "terseLabel": "NYSE CHICAGO, INC." } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "NEW YORK STOCK EXCHANGE, INC." } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2022", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001628280-23-001516-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-001516-xbrl.zip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